Pharma IP Alert: Tirzepatide P-IV Storm Hits FDA, US Generic Tariffs Loom, & Pfizer Tafamidis Discovery Ruling

Summary: Two-minute read

In this issue of the API and IP Newsletter, we break down the high-stakes Paragraph IV ANDA filings for Tirzepatide (Mounjaro & Zepbound) following the NCE-1 opening date. We also analyze proposed US generic drug tariffs of up to 200%, evaluate Patrys’ 505(b)(2) rapid injectable quetiapine for ICU delirium, and unpack a crucial Delaware District Court ruling on third-party discovery confidentiality in Pfizer v. Apotex (Tafamidis).

Key Highlights & Strategic Takeaways

1. Tirzepatide (Mounjaro / Zepbound) Paragraph IV Wave

• Massive Generic Interest: On May 13, 2026, NCE-1 eligibility date, the FDA received four distinct categories of ANDA filings targeting Eli Lilly’s blockbuster molecule, which generated $36.5B in 2025 and holds a projected peak market of $50B–$65+B globally.

• Why 4 Different ANDA Entries? Driven by two distinct NDAs (Mounjaro for T2D vs. Zepbound for Obesity) and two delivery formats (Autoinjector Pen vs. Single-Dose Vial).

• Autoinjector Battleground: The autoinjector pen saw the fiercest competition, drawing 12–13 ANDAs for Mounjaro and 11–12 ANDAs for Zepbound.

• Vial Alternative Strategy: Select generic filers chose non-autoinjector vials (1–2 for Mounjaro, 2–3 for Zepbound) to avoid complex pen-device patent litigation while securing a lower-risk first-to-file (FTF) position.
• Commercial Launch Timeline: Despite early DMF and ANDA submissions, listed Orange Book patents running through 2039–2041 make generic launches prior to 2036–2038 highly unlikely.

2. Global Supply Chains & Regulatory Updates

• US Generic Drug Tariff Threat: US President Donald Trump announced plans to impose 100% tariffs on generic drugs within two years, increasing to 200% thereafter. Aimed at reshoring active pharmaceutical ingredient (API) and finished dose manufacturing, this policy poses significant supply-chain risks for overseas generic suppliers (especially Indian pharma).

• Patrys’ ICU Delirium Breakthrough: Biotech firm Patrys is advancing a proprietary injectable formulation of Quetiapine targeting the $2B+ acute delirium market in ICU settings. Operating via a 505(b)(2) regulatory pathway (3–5 year timeline, $20M–$30M cost), the injectable provides a rapid onset compared to standard 1–2 hour oral absorption.

3. IP & Litigation Focus: Pfizer Inc. v. Apotex Inc. (Tafamidis)

• The Dispute: In ongoing Hatch-Waxman litigation over Vyndamax (Tafamidis 61 mg), defendant Apotex sought to compel Pfizer to produce confidential settlement and technical documents from a prior lawsuit involving Cipla, Dexcel, and Hikma.

• Court Ruling: The District Court of Delaware granted in part and denied in part the prior defendants' Motion to Intervene.

  • Confidentiality (Win for Prior Filers): Nonparties Cipla, Dexcel, and Hikma were allowed to intervene solely to protect their trade secrets and sensitive technical dossiers from competitor exposure.

  • Relevancy (Denied): Nonparty intervenors lack legal standing to object to discovery on relevancy grounds; the burden remains with named litigants.

• Industry Takeaway: Prior to settling, generic filers must proactively monitor subsequent litigation involving the same patent landscape to file targeted interventions under Federal Rule of Civil Procedure 24 to preserve confidential trade secrets.

#Pharma #Tirzepatide #Mounjaro #Zepbound #FDA #ANDAFiling #505b2 #PharmaNews #IntellectualProperty

----------------XX---------------XX--------------------

Thank you for the reading summary. I recommend you read the detailed blog post below. 

Contents

Recent P-IV filings

General information

Generic Drug Tariff Threat: Implications for Indian Pharma and Global Supply Chains

Patrys Reformulates Proven Quetiapine Drug for Rapid Injectable Treatment of Delirium in ICU Patients

Intellectual Property

District Court Order: Pfizer Inc. v. Apotex Inc.

Recent P-IV filings

We follow P-IV filings on the FDA website. The recent update was on 15 July 2026.  

There are 4 Different first applicant ANDAs with Paragraph IV Certifications for Tirzepatide.

The FDA’s Paragraph IV Patent Certifications list shows four separate submission entries for Tirzepatide. Why are there four P-IV ANDA filers for Tirzepatide? This is due to two main regulatory factors.

Two Separate NDAs (Brands / Indications): Eli Lilly holds two distinct NDAs for Tirzepatide:

1. Mounjaro (NDA 215866): Approved for Type 2 Diabetes Mellitus.
2. Zepbound (NDA 217806): Approved for Chronic Weight Management / Obesity.

Two Delivery Presentations (Device vs. Vial): Eli Lilly lists patents for two physical product presentations under each NDA in the FDA Orange Book:

1. Autoinjector (Single-Dose Pen): The primary commercial device presentation.
2. Single-Dose Vial (Subcutaneous Solution): The plain solution/vial presentation.

To secure first-to-file (FTF) status and eligible 180-day market exclusivity across all commercial forms, generic applicants filed separate ANDAs specifically referencing each NDA and delivery device combination on the exact NCE-1 eligibility date (May 13, 2026).

Commercial Context and Peak Sales Potential

1. 2025 Actual Revenue: The Tirzepatide franchise generated $36.5 billion in combined global sales in 2025 ($22.97 billion for Mounjaro and $13.54 billion for Zepbound). US Share: ~$25.5 Billion (~70% of global sales).
2. Peak Sales Forecast: Industry analysts project global peak annual revenues for Tirzepatide to range from $50 billion to $65+ billion, positioning it among the highest-grossing pharmaceutical molecules in history.

Mounjaro Autoinjector (NDA 215866): The Primary Diabetes Battleground.

The autoinjector presentation of Mounjaro stands as the most contested segment of Eli Lilly’s diabetes portfolio, drawing a massive 12 to 13 first-applicant ANDA filings on May 13, 2026. Covering all six commercial strengths (2.5 mg to 15 mg/0.5 mL), generic developers are targeting listed Orange Book patents extending out to December 2041. With Mounjaro generating nearly $23 billion in 2025 alone, securing shared 180-day exclusivity here could be a significant advantage. The sheer volume of filers guarantees complex multi-party Paragraph IV litigation over pen-device mechanisms and formulation patents in the months ahead.

Zepbound Autoinjector (NDA 217806): Unlocking the Mega-Obesity Market

Generic manufacturers heavily targeted Eli Lilly’s obesity-branded autoinjector, with 11 to 12 ANDA filers submitting Paragraph IV certifications on the NCE-1 date. Targeting NDA 217806 across all six subcutaneous dosage strengths, filers are seeking to bypass listed patents running through July 2039. Zepbound witnessed explosive growth to $13.5 billion in 2025, driven by surging global demand for weight-loss therapies. By establishing first-applicant status on the autoinjector device, generic players are positioning themselves to capture early market share in one of the fastest-growing therapeutic categories in pharma history.

Mounjaro Solution/Vial (NDA 215866): A Specialised Niche Strategy

Beyond the autoinjector pen, 1 to 2 ANDA applicants submitted Paragraph IV filings targeting the plain subcutaneous solution vial presentation of Mounjaro. Filed on May 13, 2026, this pathway avoids the complex intellectual property landscape surrounding pre-filled autoinjector devices. While representing a smaller immediate commercial footprint than single-dose pens, vial filings offer a streamlined development path with lower device-related regulatory hurdles. This niche entry allows select filers to secure a defensible FTF position in the type 2 diabetes market with significantly reduced litigation exposure.

Zepbound Solution/Vial (NDA 217806): Streamlined Entry into Weight Management

Targeting the non-autoinjector vial presentation of Zepbound, 2 to 3 first-applicant ANDAs were received by the USFDA on the NCE-1 opening date. By referencing NDA 217806 without copying the autoinjector mechanism, these filers focus directly on the active tirzepatide formulation patents expiring in July 2039. Vials provide a critical supply alternative during periods of widespread GLP-1/GIP pen shortages, offering generic firms a cost-effective, high-yield entry into the market. This strategy allows filers to participate in the booming obesity space while bypassing the potential patent battles over pen devices.

There are many DMF filers, and numerous generic companies have submitted an ANDA. However, considering the OB-listed patents, launching a generic before 2036-2038 appears difficult. 

General information

Generic Drug Tariff Threat: Implications for Indian Pharma and Global Supply Chains

US President Donald Trump recently announced that tariffs on generic drugs will be raised to 100% after 2 years and to 200% thereafter, aimed at “reshoring” generic pharmaceutical production to the US. 

He warned that companies choosing not to build plants in the US would be “penalised.”

News here

Patrys Reformulates Proven Quetiapine Drug for Rapid Injectable Treatment of Delirium in ICU Patients

Key Points

1. Patrys Limited is developing a proprietary injectable quetiapine formulation for delirium treatment in ICU and aged care settings
2. The injectable formulation offers an immediate onset compared to oral quetiapine, which has a 1–2 hour onset of action
3. Development timeline estimated at 3–5 years with costs of approximately US$20–30 million versus US$1.2 billion for traditional new drug discovery
4. Patrys holds provisional patent protection in Australia with no trailing obligations, and filed a new provisional patent application in 2026 for the reformulated product
5. The addressable market for delirium treatment is estimated at over US$2 billion per year globally
6. Board comprises experienced directors in biotech commercialisation, ASX governance, capital markets, and clinical trial operations

News here

Intellectual Property 

District Court Order: Pfizer Inc. v. Apotex Inc. 

In July 2026, the District Court for the District of Delaware issued a Memorandum Order addressing a Motion to Intervene filed by nonparties Cipla Limited, Dexcel Pharma Technologies Limited, and Hikma Pharmaceuticals USA Inc. (Proposed Intervenors). The Court granted in part and denied in part the motion, permitting the Proposed Intervenors to intervene solely to raise confidentiality objections to requested discovery, while denying their standing to raise relevancy objections. 

Background

This is about Tafamidid litigation.

The earlier litigation was Pfizer Inc. et al. v. Cipla Limited, Dexcel Pharma Technologies Ltd., and Hikma Pharmaceuticals USA Inc. in the U.S. District Court for the District of Delaware, filed in 2022/2023. 

• In that suit, Pfizer asserted three patents covering Vyndamax (tafamidis) U.S. Patent Nos. 7,214,695; 7,214,696; and 9,770,441. 
• That lawsuit ended when Pfizer reached separate confidential settlement agreements and stipulations of dismissal with Cipla, Dexcel, and Hikma. 

• Now, in subsequent litigation, Apotex requested that the court order Pfizer to produce confidential files, technical documents, and settlement agreements from an earlier lawsuit Pfizer had brought against three other generic companies, namely Cipla, Dexcel, and Hikma. 
• Cipla, Dexcel, and Hikma stepped in (intervened) to protect their trade secrets, asking the court to block Apotex from seeing those sensitive documents. 

What the Judge Decided

• On Confidentiality (Win for Cipla/Dexcel/Hikma): The judge allowed them to join the case specifically to fight to keep their trade secrets and confidential business data private. 
• On Relevance (Win for Apotex/Pfizer process): The judge refused to let them argue whether the documents are "relevant" to Apotex's case, ruling that non-parties cannot challenge discovery on relevance grounds (and Pfizer is already handling that argument). 

Here are the key learnings and strategic implications of this judgment:

• Protecting Prior Trade Secrets: Non-party generic filers who previously settled patent litigation can successfully intervene under Federal Rule of Civil Procedure to safeguard their confidential technical data, trade secrets, and settlement terms from being exposed in subsequent competitor lawsuits. 
• Strict Limits on Non-Party Standing: Third parties lack standing to challenge discovery requests on relevancy grounds; courts expect the named litigants (e.g., Pfizer) to bear the burden of opposing irrelevant fishing expeditions. 
• Impact on ANDA Defence Strategies: Subsequent Paragraph IV filers (such as Apotex) will routinely seek to leverage invalidity positions and scientific disclosures from earlier, settled generic challengers (Cipla, Dexcel, and Hikma) to accelerate their own defence. 
• Strategic Takeaway for Generics: When entering into confidential settlements with innovator companies, generic filers must remain vigilant during subsequent litigation involving the same patent to file timely, targeted interventions that ensure their proprietary technical dossiers remain strictly protected.

Decision here